Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed and Paclitaxel for Second-line Gastric or GEJ Adenocarcinoma
NCT03083613Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2015
- Primary completion
- Sep 2017
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed and Paclitaxel Micelles for Injection in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate. Started May 2015; status: completed.
02
Drugs
raltitrexedPaclitaxel Micelles for Injection
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03083613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083613.